BioSpace News Archive

Biotech Bay

Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC

Net proceeds to the Company from the Registered Direct Offering are approximately $0.49 million, which Jaguar intends to use for the ongoing commercialization of Mytesi, the Company’s lead prescription drug product, and for working capital and general corporate purposes.

November 27, 2017

·

6 min read

Business

Fresenius Medical Care Achieves Improved Health Outcomes and Savings Through National Medicare Demonstration Program

This success was validated by an independent report from Lewin Group, which showed a nearly nine percent decrease in hospitalization rates for these patients during the same time.

November 27, 2017

·

4 min read

Business

XTL Biopharma Reports Third Quarter 2017 Financial Results

XTL reported approximately $6,085 thousand in cash and cash equivalents as of September 30, 2017, an increase of $4,066 thousand since December 31, 2016.

November 27, 2017

·

12 min read

Business

Stratasys Inks Deal to Bring Advanced 3D Printed Medical Modeling to Global Health Tech Leader Philips

The agreement includes virtually seamless interfacing and dedicated workflows across Philips IntelliSpace Portal 10 and Stratasys Direct Manufacturing’s parts-on-demand service.

November 27, 2017

·

5 min read

FDA

MorphoSys Announces That its Licensee Janssen Has Received Approval for Tremfya (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis

MorphoSys is eligible to receive royalties on net sales of Tremfya.

November 27, 2017

·

3 min read

Drug Development

European Commission Approves Tremfya (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

The EC approval is based on data from three Phase III clinical studies. The VOYAGE 1 and 2 trials, which compared guselkumab with placebo and HUMIRA.

November 27, 2017

·

9 min read

Business

TSO3 Announces the Death of Mr. Jean Lamarre

Mr. Lamarre contributed sound and constructive counsel on TSO3’s Board of Directors, and while leading TSO3’s Human Resources Committee.

November 27, 2017

·

1 min read

Business

Inflection Biosciences and RCSI Enter Research Collaboration to Target Therapy-Resistant Breast Cancer

Inflection Biosciences and RCSI, today announced a research collaboration that aims to understand mechanisms of resistance to major breast cancer therapies and examine potential new treatments of Inflection Biosciences for patients with a cancer that does not respond effectively to existing therapies.

November 27, 2017

·

4 min read

Business

Orchard Therapeutics Announces Extension of its Collaboration with Manchester University to Include Sanfilippo Syndrome Type B

Orchard Therapeutics announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B from The University of Manchester, UK.

November 27, 2017

·

6 min read

Drug Development

Biohaven Completes Enrollment in Second Pivotal Phase III Clinical Trial of Oral CGRP-Receptor Antagonist Rimegepant

The trial began shortly after the commencement of rimegepant’s first efficacy trial, Study BHV3000-301, and the two trials enrolled simultaneously with the objective of announcing topline results for the migraine program in the first quarter of 2018.

November 27, 2017

·

6 min read